Phlegmatic Pfizer

Updated Dec. 1, 2003 12:01 a.m. ET

The drug industry leader doesn't enjoy a leading price/earnings multiple, as investors question how fast the company can grow. Pfizer's R&D spending and knack for partnering with other drug developers should spur sales.